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Abstract
Purpose To determine the prognostic value of tumor-induced
cortical bone destruction at computed tomography (CT) in
newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Materials and methods This retrospective study included 105
patients with newly diagnosed DLBCL who had undergone
CT and bone marrow biopsy (BMB) before R-CHOP (rituxi-
mab, cyclophosphamide, hydroxydaunorubicin, Oncovin, and
prednisolone) chemo-immunotherapy. Cox regression analy-
ses were used to determine the associations of cortical bone
status at CT (absence vs. presence of tumor-induced cortical
bone destruction), BMB findings (negative vs. positive for
lymphomatous involvement), and dichotomized National
Comprehensive Cancer Network International Prognostic In-
dex (NCCN-IPI) strata (low risk vs. high risk) with
progression-free survival (PFS) and overall survival (OS).
Results Univariate Cox regression analysis indicated that cor-
tical bone status at CT was no significant predictor of either
PFS or OS (p=0.358 and p=0.560, respectively), whereas
BMB findings (p=0.002 and p=0.013, respectively) and di-
chotomized NCCN-IPI risk strata (p=0.002 and p=0.003, re-
spectively) were significant predictors of both PFS and OS. In
the multivariate Cox proportional hazards model, only the
dichotomized NCCN-IPI score was an independent predictive
factor of PFS and OS (p=0.004 and p=0.003, respectively).
Conclusions The presence of tumor-induced cortical bone de-
struction at CT was not found to have any prognostic impli-
cations in newly diagnosed DLBCL.
Keywords Bonemarrow . Cortical bone . CT . Diffuse large
B-cell lymphoma . Prognosis
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
non-Hodgkin lymphoma, making up approximately 30 to
35 % of all cases [1, 2]. Diagnosis of bone marrow involve-
ment is important in DLBCL, because it is an adverse prog-
nostic factor with potential consequences for treatment plan-
ning [1–3]. Blind bone marrow biopsy (BMB) of the posterior
iliac crest is therefore a standard staging procedure in these
patients [4]. 18F-fluoro-2-deoxy-D-glucose positron emission
tomography/computed tomography (FDG-PET/CT) may be
used complementary or as a partial alternative to BMB for
the detection of bone marrow evaluation in DLBCL [5]. Un-
fortunately, several recent studies have indicated that, unlike
BMB-based bone marrow status, FDG-PET/CT-based bone
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marrow status is not predictive of progression-free survival
(PFS) and overall survival (OS) [6–8]. Although the reason
for the lack of prognostic value of FDG-PET/CT in this setting
is still unclear, it indicates that focal FDG-avid bone marrow
lesions that are presumed to be lymphomatous are clinically
irrelevant in this context.
CT, either alone or in combination with FDG-PET, is a
compulsory staging procedure in DLBCL [4]. Although
CT is not an appropriate method to assess the bone mar-
row and to detect lymphomatous lesions that are confined
to the bone marrow [9], it is the best method to evaluate
the cortical bone. CT scans of patients with DLBCL some-
times show tumor-induced cortical bone destruction, either as
a result of lymphoma extending from the bone marrow to the
bony cortex, or as a result of extramedullary lymphoma grow-
ing into the adjacent bony cortex. Although cortical destruc-
tion shown at CT indicates that the underlying DLBCL has an
aggressive tumor growth, the prognostic implications of this
finding are still unclear.
The purpose of this study was to determine the prognostic
value of tumor-induced cortical bone destruction at CT in
newly diagnosed DLBCL patients who are treated with R-
CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin,
Oncovin, and prednisolone) chemo-immunotherapy.
Materials and methods
Study design and patient population
This retrospective study was approved by the local institution-
al review board and the requirement for written informed con-
sent was waived. All patients with newly diagnosed DLBCL
routinely undergo pretreatment CT at our institution. The hos-
pital’s database (which identifies patients on the basis of their
clinical diagnosis) was searched for all patients who were
newly diagnosed with DLBCL between January 2004 and
December 2013. Study inclusion criteria were: newly diag-
nosed and histologically proven DLBCL, availability of CT
(either full-dose CT or low-dose CT as part of an FDG-PET
examination) from skull base to upper thigh, availability of
blind bone marrow biopsy (BMB) of the iliac crest with a time
interval between CTand BMB <30 days, availability of serum
lactate dehydrogenase (LDH) measurement, and treatment
with the R-CHOP regimen. Study exclusion criteria were:
primary mediastinal DLBCL (which is regarded as a different
disease entity), previously treated/relapsed lymphoma, trans-
formed lymphoma, coexistence of another lymphoma subtype
in the diagnostic biopsy, another malignancy within the pre-
vious 5 years, and start of treatment before CT.
CT acquisition
CT scans were acquired using either a stand-alone 16-detector
row CT system (Somatom Sensation 16, Siemens Healthcare,
Erlangen, Germany) or a 40-detector row integrated PET/CT
system (Biograph 40 TruePoint PET/CT, Siemens Healthcare,
Erlangen, Germany). All patients ingested 780 ml of oral
Fig. 2 Example of tumor-
induced cortical destruction at CT
in a 49-year-old man with newly
diagnosed DLBCL. Axial CT
shows focal destruction of the
right fifth rib (arrow) with
surrounding soft tissue mass
Fig. 1 Example of tumor-induced cortical destruction at CT in a 69-year-
old woman with newly diagnosed DLBCL. Axial CT shows pathological
densities in both iliac wings, indicating lymphomatous bone marrow
involvement, and a focal disruption of the bony cortex (arrow)
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contrast agent (750 ml of water mixed with 30 ml of Telebrix
Gastro, Guerbet, Gorinchem, The Netherlands), 2 h before
image acquisition. Full-dose CT from skull base to upper
thigh was performed in the portal venous phase, following
intravenous administration of a non-ionic iodinated contrast
agent (Omnipaque 300 [GE Healthcare, Eindhoven, the Neth-
erlands] for Somatom Sensation 16 or Xenetix 300, [Guerbet,
Gorinchem, The Netherlands] for Biograph 40 TruePoint
PET/CT), using the following settings: 120 kV, 90 mA
(Somatom Sensation 16) or 60–160 mAs (automatic dose
modulation) (Biograph 40 TruePoint PET/CT), pitch of 0.8,
0.5-s (Somatom Sensation 16) or 0.8-s (Biograph 40
TruePoint PET/CT) tube rotation time, and 1.5-mm slice
width. Typical CTDIvol values for full-dose CT scanning
was around 4.0 mGy for premonitoring of the intravenous
bolus, 28.3 mGy for monitoring of the intravenous bolus,
6.5 mGy for neck CT, 7.6 mGy for chest CT, and 13.3 mGy
for abdomen CT. A subset of patients only underwent non-
intravenous contrast-enhanced low-dose CT as part of their
FDG-PET/CT examination, which was acquired with the fol-
lowing settings: 120 kV, 26–30 mAs (automatic dose modu-
lation), pitch of 1.2, 0.8-s tube rotation time, and 1.5-mm slice
width. Typical CTDIvol value for low-dose CT scanning was
around 1.7 mGy. A smooth reconstruction kernel was used,
and CT images were reconstructed to contiguous axial, coro-
nal, and sagittal 5-mm slices.
Image interpretation
A reader with more than 5 years of clinical CT experience
(T.C.K) evaluated the CT images for the presence of tumor-
induced cortical bone destruction. The reader was blinded to
clinical, laboratory, and other imaging findings, and patient
outcome. Tumor-induced cortical destruction was defined as
non-integrity of the bony cortex with underlying hypodense
(lytic) bone marrow changes, with or without associated tu-
mor mass in the surrounding soft tissues (Figs. 1 and 2). Ver-
tebral body collapse was only considered positive for tumor-
induced cortical destruction if focal or epidural soft tissue
masses and/or involvement of the pedicles was also present
[10]. If present, the maximum diameter in any plane of the
largest area of cortical bone destruction was measured. The
reader also evaluated all CT scans for the presence and extent
of nodal and extramedullary extranodal disease. For this pur-
pose, any lymph node measuring more than 10 mm in short-
axis diameter in the axial plane was considered positive for
lymphoma [11]. Focal areas with abnormal attenuation and
masses in extranodal organs were also considered positive
for lymphoma, excluding obviously benign lesions such as
cysts and hemangiomas. Splenomegaly (splenic index ex-
ceeding 725 cm3 [12]) was regarded positive for lymphoma,
but hepatomegaly was not. Subsequently, presence of
extranodal disease in major organs (bone marrow, central








Patients (no.) 8 97
Age
Mean±SD (years) 68.4±12.0 63.6±13.9
Median (years) 68.5 65.0
Range (years) 49–83 24–87
Male/Female 3/5 54/43
Positive/negative BMB 3/5 16/81
NCCN-IPI factors
Age
≤40 years 0 7
>40 to ≤60 years 2 27
>60 to ≤75 years 3 44
>75 years 3 19
ECOG PS>1 1 16
LDH>ULN
≤1 4 28
>1 to ≤3 4 56
>3 0 13





Low risk (0–1) 0 8
Low-intermediate risk (2–3) 2 22
High-intermediate risk (4–5) 4 49
High risk (≥6) 2 18
Follow-up time of surviving patients
Mean±SD (days) 647±490 1,542±914
Median (days) 511 1325





Death (No.) 1 32
*For the purpose of this study, only histologically proven bone marrow
involvement was used to define stage IV disease, as recommended by
Zhou et al. [3]. Imaging-based bone marrow involvement only (i.e., the
presence of tumor-induced cortical bone destruction at CT) was not used
to define stage IV disease
**Defined as either bone marrow, central nervous system, liver/
gastrointestinal tract or lung involvement, with histological confirmation
of bone marrow and central nervous system involvement, as recommend-
ed by Zhou et al. [3]
BMB bone marrow biopsy, ECOG PS Eastern Cooperative Oncology
Group Performance Score, LDH lactate dehydrogenase, NCCN-IPI Na-
tional Comprehensive Cancer Network International Prognostic Index,
SD standard deviation,ULN upper limit of normal (according to the local
reference values of each participating institution)
Skeletal Radiol (2015) 44:687–694 689
nervous system, liver/gastrointestinal tract or lung) and Ann
Arbor stage (stage I-IV) [13] were recorded for subsequent
National Comprehensive Cancer Network (NCCN) Interna-
tional Prognostic Index (IPI) scoring [3].
BMB
Unilateral BMB of the posterior iliac crest was acquired by
different hematologists and evaluated by different
hematopathologists, as part of standard care.
NCCN-IPI
Age, serum LDH levels, presence of extranodal disease in
major organs (either bone marrow, central nervous system,
liver/gastrointestinal tract or lung involvement), presence of
Ann Arbor stage III/IV disease, and Eastern Cooperative On-
cology Group (ECOG) performance status score of each pa-
tient were recorded at time of diagnosis to calculate anNCCN-
IPI score [3]. For the purpose of this study, only histologically
confirmed bone marrow involvement, and not imaging-based
bone marrow involvement, was used to define stage IV dis-
ease and extranodal involvement, as recommended by Zhou
et al. [3]. The four NCCN-IPI risk groups (low risk [scores 0–
1], low-intermediate risk [scores 2–3], high-intermediate risk
[scores 4–5] and high risk [scores 6–8]) were dichotomized
into low risk (comprising low and low-intermediate risk pa-
tients) and high risk (comprising high-intermediate and high-
risk patients) groups.
Patient follow-up
Clinical follow-up and either follow-up stand-alone FDG-
PET with stand-alone CT or integrated FDG-PET/CT were
used in all patients to determine if and when relapsed or
progressive disease had occurred, in line with the Revised
Response Criteria for Malignant Lymphoma [14]. PFS was
calculated from the date of diagnosis to documented disease
relapse/progression or, for patients dying as a result of causes
unrelated to DLBCL or the lymphoma treatment, the date of
death. For surviving patients who did not experience disease
relapse/progression, follow-up was censored at the date the
patient was last known to be alive. OS was calculated from
the date of diagnosis until death as a result of any cause or, in
surviving patients, censored at the date last known to be alive.
Statistical analysis
Associations between cortical bone status at CT (absence vs.
presence of tumor-induced cortical bone destruction) and the
NCCN-IPI factors categorized age (≤40, 40–60, 60–75, and
>75 years), categorized LDH ratio (≤1, 1–3 or >3 upper limit
of normal), presence of extranodal disease in major organs
(either bone marrow [histologically confirmed], central ner-
vous system, liver/gastrointestinal tract or lung), presence of
Ann Arbor stage III/IV disease, and ECOG performance sta-
tus (≥2) were assessed using Spearman (ρ) (for ordinal
NCCN-IPI factors) or Phi (φ) (for binary NCCN-IPI factors)
correlation coefficient analyses [15].
PFS and OS were analyzed using the Kaplan–Meier meth-
od with log-rank test for comparison of differences [16], ac-
cording to cortical bone status at CT (absence vs. presence of
tumor-induced cortical bone destruction), BMB findings (neg-
ative vs. positive for lymphomatous involvement), and dichot-
omized NCCN-IPI risk strata (low risk vs. high risk). Subse-
quently, univariate and multivariate Cox regression analyses
were performed to determine the influence of cortical bone
status at CT, BMB findings, and dichotomized NCCN-IPI risk
strata on PFS and OS.
Fig. 3 Kaplan–Meier curves for PFS (a) and OS (b) of patients with
tumor-induced cortical destruction at CT vs. patients without tumor-
induced cortical destruction at CT. Patients with tumor-induced cortical
destruction at CT had no significantly different PFS and OS than those
without (log-rank test, p=0.341 and p=0.554, respectively)
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Two-sided p values less than 0.05 were considered to indi-
cate a statistically significant difference. Statistical analyses




A total of 208 patients were newly diagnosed with DLBCL
between January 2004 and December 2013. Of these 208
patients, four were excluded because of primary mediastinal
DLBCL, 15 were excluded because of transformed lympho-
ma, 18 were excluded because of coexistence of another lym-
phoma subtype in the diagnostic biopsy, four were excluded
because of another malignancy within the previous 5 years, 23
were excluded because of non-availability of CT from skull
base to upper thigh, 22 were excluded because of lack of
BMB, four were excluded because of a BMB of poor, non-
diagnostic quality, three were excluded because the time in-
terval between CT and BMB exceeded 30 days, and ten were
excluded because they received no or another treatment than
R-CHOP regimen. Finally, 105 patients (57 men and 48 wom-
en, mean age, 63.9 years, age range, 24–87 years) were in-
cluded. Detailed patient characteristics are shown in Table 1.
Cortical bone status at CT
Tumor-induced cortical bone destruction at CTwas present in
eight of 105 (7.6 %) patients, and was located in the cranium
(n=1), nasal bone (n=1), mandible (n=1), clavicle (n=1), ribs
(n=1), iliac wings (n=1) and sacrum (n=2). An associated
tumor mass in the surrounding soft tissues was found in three
of these eight (37.5 %) patients. The meanmaximum diameter
of the largest area of cortical bone destruction in those eight
Fig. 4 Kaplan–Meier curves for PFS (a) and OS (b) of patients with negative BMB vs. those with positive BMB. Patients with a positive BMB had
significantly worse PFS and OS than those with a negative BMB (log-rank test, p=0.001 and p=0.001, respectively)
Fig. 5 Kaplan–Meier curves for PFS (a) and OS (b) of patients with low risk NCCN-IPI scores vs. high-risk NCCN-IPI scores. Patients with high-risk
NCCN-IPI scores had significantly worse PFS and OS than those with low risk NCCN-IPI scores (log-rank test, p<0.001 and p<0.001, respectively)
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patients was 3.5 cm (range, 2–4.5 cm). Representative exam-
ples are shown in Figs. 1 and 2.
BMB
BMB was positive for lymphoma in 19 of 105 (18.1 %) pa-
tients. Only 3/19 (16 %) patients had tumor-induced cortical
bone destruction.
Correlations between cortical bone status at CT
and NCCN-IPI factors
There were no correlations between cortical bone status at CT
and the NCCN-IPI factors categorized age (ρ=0.111, p=
0.261) categorized LDH ratio (ρ=−0.146, p=0.138), presence
of extranodal disease in major organs (φ=0.146, p=0.136),
presence of Ann Arbor stage III/IV disease (φ=0.048, p=
0.625), and ECOG performance status (φ=−0.029, p=0.769).
Patient follow-up
The median follow-up time of surviving patients was 1,
454 days (range, 134–3,597 days). Of 105 patients, 37
(35.2 %) experienced disease relapse/death, and 33 patients
(31.4 %) died (Table 1).
Prognostic value of tumor-induced cortical bone destruction
at CT
Patients with tumor-induced cortical bone destruction at CT
had no significantly different PFS and OS than those without
(log-rank test, p=0.341 and p=0.554, respectively) (Fig. 3).
PFS and OS were significantly worse in patients with a posi-
tive BMB (log-rank test, p=0.001 and p=0.001) (Fig. 4) and
in patients with a high-risk NCCN-IPI score (log-rank test,
p<0.001 and p<0.001, respectively) (Fig. 5). Univariate
Cox regression analysis indicated that cortical bone status at
CTwas no significant predictor of either PFS or OS (p=0.358
and p=0.560, respectively), whereas BMB findings (p=0.002
and p=0.013, respectively) and dichotomized NCCN-IPI risk
strata (p=0.002 and p=0.003, respectively) were significant
predictors of both PFS and OS (Table 2). In the multivariate
Cox proportional hazards model, only the dichotomized
NCCN-IPI score was an independent predictive factor of
PFS and OS (p=0.004 and p=0.003, respectively) (Table 3).
Discussion
The results of this study show that the incidence of tumor-
induced cortical bone destruction is low (i.e., less than
10 %) in newly diagnosed DLBCL. Interestingly, cortical
bone destruction was observed in only 16 % (three out of 19
patients) with BMB-proven bone marrow involvement. Thus,
in most patients, bone marrow involvement does not result in
osteolysis. Most importantly, tumor-induced cortical bone de-
struction is not associated with any of the established NCCN-
IPI factors, and is not associated with a worse PFS or OS. It
can be speculated that although cortical bone destruction in-
dicates an aggressive tumor growth, it does not indicate the
presence of an R-CHOP-resistant phenotype. On the other
hand, both BMB findings and the (dichotomized) NCCN-IPI
Table 2 Cox regression analysis of PFS
Characteristic Univariate analysis Multivariate analysis
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
Tumor-induced cortical destruction at
CT vs. no tumor-induced cortical
destruction at CT
0.393 0.054–2.854 0.358 – – –
BMB positive vs. BMB negative 3.013 1.501–6.048 0.002 – – –
NCCN-IPI high risk vs. NCCN-IPI low risk 21.774 3.000–158.078 0.002 21.774 3.000–158.078 0.002
Table 3 Cox regression analysis of OS
Characteristic Univariate analysis Multivariate analysis
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
Tumor-induced cortical destruction at
CT vs. no tumor-induced cortical
destruction at CT
0.551 0.075–4.033 0.559 – – –
BMB positive vs. BMB negative 2.588 1.229–5.448 0.013 – – –
NCCN-IPI high risk vs. NCCN-IPI low risk 20.186 2.768–147.191 0.003 20.186 2.768–147.191 0.003
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risk strata were associated with PFS and OS, with BMB-
positive patients and patients with high-risk NCCN-IPI scores
showing worse outcome than BMB-negative patients and pa-
tients with low-risk NCCN-IPI scores, respectively. However,
unlike BMB status, only the NCCN-IPI risk score remained as
an independent predictive factor of both PFS and OS, which is
in line with the recent publication by Zhou et al. [3]. The latter
finding can be explained by the fact that BMB status is already
part of the NCCN-IPI [3].
Given the fact that approximately one-third of patients with
DLBCL still develop relapsed/refractory disease [1, 2], efforts
are being made to identify new prognostic biomarkers that
improve risk stratification in this disease. Unlike imaging-
based bone marrow involvement, the presence of histological-
ly confirmed bone marrow involvement is already an
established negative prognostic factor in DLBCL, and is part
of the current NCCN-IPI [3]. A disadvantage of BMB, how-
ever, is the fact that it assesses only a very small part of the
bone marrow, thus being prone to sampling errors. Cross-
sectional whole-body imaging modalities like FDG-PET and
magnetic resonance imaging (MRI) have the advantage of
being able to visualize the entire bone marrow, and it was
hoped that bone marrow assessment with these techniques
would improve prognostication. Although the role of MRI in
this setting needs further investigation [17], the majority of
studies on this topic have indicated that FDG-PET/CT-based
bone assessment has no prognostic implications in DLBCL
[6–8, 18]. CT is not an appropriate technique to evaluate the
bone marrow [9], but is an ideal method to evaluate the bony
cortex. Although lymphoma-induced cortical bone destruc-
tion indicates aggressive tumor growth, the hypothesis that
this would be associated with a poorer outcome was not sup-
ported by the findings of the present study.
The prognostic impact of cortical bone destruction has
been examined previously by Lee et al. [19]. Their study in-
cluded patients diagnosed with DLBCL between 1994 and
2009. The PFS of 60 patients with bone lesions was compared
with those of 181 patients with stage IV disease and similar
IPI scores but without bone destruction. The PFS was not
significantly different (p=0.457) between two groups. Lee
et al. [19] concluded that bone involvement may not have an
additive adverse impact on the prognosis of Ann Arbor stage
IV DLBCL, both in their entire study population (which in-
cluded patients treated with different therapies) as well as in
the subgroup of patients treated with R-CHOP. However,
drawbacks of the study by Lee et al. [19] are that criteria for
bone involvement were not reported, that the prognostic im-
pact of bone involvement was assessed using matched con-
trols rather than assessing the additional impact in the entire
group of DLBCL patients over de NCCN-IPI and other risk
factors using Cox regression, and that controls were selected
on the basis of the old IPI [20] rather than the recently pub-
lished NCCN-IPI [3].
This study had several limitations. First, the number of
patients with cortical bone destruction was low. A future study
with sufficient power may be necessary to confirm the present
findings. Second, although the majority of patients had under-
gone full-dose CT, several patients received a low-dose CT
scan only, as part of their FDG-PET/CT examination. In ad-
dition, a smooth reconstruction kernel was used and CT im-
ages were reconstructed to 5-mm slices. These factors may
have had a negative impact on bony lesion detection. Third,
although the NCCN-IPI defines four risk groups (low risk,
low-intermediate risk, high-intermediate risk, and high risk),
patients were dichotomized in low-risk (including low and
low-intermediate risk patients) and high-risk (including
high-intermediate and high risk patients) groups for survival
analyses, because of the relatively limited sample size of the
present study.
In conclusion, the presence of tumor-induced cortical bone
destruction at CT was not found to have any no prognostic
implications in newly diagnosed DLBCL. The NCCN-IPI re-
mains the most important method for the prognostication of
this disease.
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